TIGIT+ Tregs in the TME are linked to poor clinical outcomes for patients with various malignancies, including NSCLC, melanoma, and colorectal cancer (CRC), emphasizing their role in immune suppression (Fourcade et al., 2018; Peng et al., 2022; Zhou et al., 2021). This evidence concerns the gene TIGIT and non-small cell lung carcinoma.